24 citations
,
July 2019 in “Reproductive Medicine and Biology” This review discusses the classification and treatment of ejaculatory dysfunction, outlining both pharmacotherapy and behavioral therapy as primary interventions, but does not present new clinical findings.
34 citations
,
December 2021 in “Journal of Clinical Medicine” This review details the prevalence and management of ejaculatory disorders in men with benign prostatic hyperplasia-related urinary symptoms and highlights the importance of preserving peri-montanal tissue during treatment to maintain antegrade ejaculation.
8 citations
,
August 2021 in “Fertility and Sterility” This review discusses the potential risks of ejaculatory dysfunction associated with both medical and surgical treatments for lower urinary tract symptoms due to benign prostatic hyperplasia and their implications for male fertility, but it reports no new clinical results.
February 2024 in “Urology” This study found that among ten identified medications associated with ejaculatory disorders, Paroxetine and Tamsulosin were mainly linked to delayed and retrograde ejaculation, while Finasteride and Sildenafil were most associated with painful ejaculation and ejaculation failure according to reports from FDA-FAERS and Eudra-Vigilance databases.
9 citations
,
April 2007 in “Journal of Andrology” This article reviews the management of excessive pre-ejaculate, highlighting case reports where 5-α-reductase inhibitors, such as finasteride and dutasteride, led to symptom resolution in patients reporting distress due to this condition.